Alzheimer's disease, some modifiable risk factors
Keywords:
Alzheimer's, modifiable risk, population strategyAbstract
Introduction: dementia is a disorder of cognition that interferes with the functioning of daily life and produces a loss of independence. Its prevalence and incidence increase with advanced age. An updated bibliographical review was carried out, which consisted of a search of specialized journals on the subject, works in Spanish and English were reviewed, and investigations of diverse design by prestigious authors on the subject were included. Objective: to update the available evidence on the modifiable risk factors associated with Alzheimer's disease (AD). Development: in recent decades, epidemiological studies reveal several risk factors for the development of this entity, among which appear the factors related to lifestyle. Population strategies for modifying these factors could potentially prevent some cases of Alzheimer's. Conclusions: Population strategies must include a global effort involving the supposedly healthy population, health professionals, and the community, to modify the way and style of life directed to the modifiable factors, so that they contribute to the knowledge of the disease to its management and the delay of its appearance.
Downloads
Download data is not yet available.
References
1. Niu H, Alvarez Alvarez I, Guillén Grima F, Aguinaga Ontoso I. Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaanálisis. Neurología [en línea]. 2016 [citado 3 Abr 2017]; 32(8):523-532. http://dx.doi.org/10.1016/j.nrl.2016.02.016)
2. Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional. Enfermedad de Alzheimer. Calidad de Vida. Bibliomed [en línea]. 2016 Dic [citado 3 Abr 2017]; 23(12): [aprox. 12 p.]. Disponible en: http://files.sld.cu/bmn/files/2016/12/bibliomed-diciembre-2016.
3. Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med. 2012; 18:181.
4. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity [en línea]. 2000; [citado 3 Abr 2017]; 13:715-725. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23178247
5. Vlad SC, Miller DR, Kowall NW, FelsonDT.Protective effects of NSAIDs on the development of Alzheimer disease. Neurology [en línea]. 2008 [citado 3 Abr 2017]; 70:1672-1677. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/18458226
6. Rocca WA, Amaducci LA, Schoemberg BS. Epidemiology of clinically diagnosed Alzheimer disease. Ann Neurol. 1998; 19:415-24.
7. Qiu C, Ronchi D de, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry. 2007; 20:380–385.
8. Launer Lj, Andersen K, Dewey M, et al. Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses. Neurology. 1999; 52(1):78-84.
9. Deborah E. Barnes, the Projected Impact of Risk Factor Reduction on Alzheimer's Disisease Prevalence. Lancet Neurol. 2011 Sept; 10(9):819–828.
10. Hsu DC, Marshall, GA. Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Curr Alzheimer Res [en línea]. 2017 [citado 4 Abr 2017]; 14(4):426-440. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329133/
11. Solórzano Romero J. Factores de riesgo de la enfermedad de Alzheimer. Rev Hosp Psiq Hab [en línea]. 2014 [citado 3 Abr 2017]; 11(3):[aprox. 7 p.]. Disponible en: http://www.revistahph.sld.cu/2014/nro%203/factores%20de%20riesgo.html
12. Moore B, Miskovski K, Stupar M, Ng H. Reducing the Prevalence of Alzheimer’s Disease: modifible risk factors or social determinants of health [en línea]. Sydney: Alzheimer’s Australia NSW; 2015. Disponible en: https://nsw.fightdementia.org.au/sites/default/files/NSW/documents/Discussion_Pap
13. Sandra K. Pope. Will a healthy lifestyle help prevent Alzheimer’s disease? Annu Rev Pub Health [en línea]. 2003; 24:111–32. doi: 10.1146/annurev.publhealth.24.100901.141015.
14. Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med. 2011; 269:107-17.
15. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, AntikainenR, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized con-trolled trial. Lancet. 2015; 385:2255-63.
16. Menéndez González M. Estilo de vida y riesgo de padecer demencia. Arch Med [en línea]. 2011 [citado 3 Abr 2017];7(31): [aprox. 16 p.]. Disponible en: http://www.archivosdemedicina.com/medicina-de-familia/estilo-de-vida-y-riesgo-de-padecer-demencia.pdf
17. Flicker L. Modifiable Lifestyle Risk Factors for Alzheimer's Disease. J Alzheimer's Dis. 2010; 20(3):803-811. Disponible en: http://content.iospress.com/articles/journal-of-alzheimers-disease/jad091624?resultNum
18. Martín P. Nutrición y demencia – resumen ejecutivo. Londres: Alzheimer’s Disease International (ADI); 2014.
19. Carnero Pardo C, Escamilla Sevilla F. “Enfermedad de Alzheimer: factores de riesgo y protectores”. En: Martínez Lage JM, Berthier Torres M: “Alzheimer 2002: teoría y práctica”. Madrid: Aula Médica Ediciones; 2002.
20. Dudkowiak R, Gryglas A, Poniewierka E. The role of diet and antioxidants in the prevention of Alzheimer's disease. J Med Sci [en línea]. 2016 [citado 3 Abr 2017]; 85(3):205-212. Disponible en: http://web.b.ebscohost.com/ehost/detail/detail?sid=e89bfc39-9925-40fc-bafb
21. Caballer García J. Los ácidos grasos omega-3 en la prevención
de la enfermedad de Alzheimer. Alzheimer Real Invest Demenc [en línea]. 2011 [citado 4 Abr 2017];49:12-18 Disponible en: http://www.revistaalzheimer.com
22. Rodrigo Valenzuela B. Ácido Docohexanoico (DHA): Una perspectiva nutricional para la prevención de la Enfermedad de Alzheimer. Rev Chil Nutr [en línea]. 2008 [citado 4 Abr 2017]; 35(Supl 1):250-261. Disponible en: http://www.scielo.cl/pdf/rchnut/v35s1/art01.pdf
23. Hussein N. Yassine, MDAMA Neurol. Association of Docosahexaenoic Acid Supplementation with Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers a Review; 2017. Disponible en: http://web.a.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=5cdc4421-2b50-400b-958a-
24. Cruz-Tioba E. Efecto antioxidante de flavonoides contra la toxicidad del amiloide-β fracción 25-35: modelo conductual de Alzheimer. Arch Neuroc. 2005;10(23): Disponible en: http://web.a.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=5cdc4421-2b50-
25. Escamilla Jiménez CI, Cuevas Martínez EY, Fonseca JG. Flavonoides y sus acciones antioxidantes [en línea]. Rev Fac Med UNAM. 2009 [citado 4 Abr 2017]; 52(2):73-75. Disponible en: http://web.a.ebscohost.com/ehost/detail/detail?vid=6&sid=224cd0ca-b701-433d-a436-0255721
2. Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional. Enfermedad de Alzheimer. Calidad de Vida. Bibliomed [en línea]. 2016 Dic [citado 3 Abr 2017]; 23(12): [aprox. 12 p.]. Disponible en: http://files.sld.cu/bmn/files/2016/12/bibliomed-diciembre-2016.
3. Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med. 2012; 18:181.
4. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity [en línea]. 2000; [citado 3 Abr 2017]; 13:715-725. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23178247
5. Vlad SC, Miller DR, Kowall NW, FelsonDT.Protective effects of NSAIDs on the development of Alzheimer disease. Neurology [en línea]. 2008 [citado 3 Abr 2017]; 70:1672-1677. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/18458226
6. Rocca WA, Amaducci LA, Schoemberg BS. Epidemiology of clinically diagnosed Alzheimer disease. Ann Neurol. 1998; 19:415-24.
7. Qiu C, Ronchi D de, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry. 2007; 20:380–385.
8. Launer Lj, Andersen K, Dewey M, et al. Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses. Neurology. 1999; 52(1):78-84.
9. Deborah E. Barnes, the Projected Impact of Risk Factor Reduction on Alzheimer's Disisease Prevalence. Lancet Neurol. 2011 Sept; 10(9):819–828.
10. Hsu DC, Marshall, GA. Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. Curr Alzheimer Res [en línea]. 2017 [citado 4 Abr 2017]; 14(4):426-440. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329133/
11. Solórzano Romero J. Factores de riesgo de la enfermedad de Alzheimer. Rev Hosp Psiq Hab [en línea]. 2014 [citado 3 Abr 2017]; 11(3):[aprox. 7 p.]. Disponible en: http://www.revistahph.sld.cu/2014/nro%203/factores%20de%20riesgo.html
12. Moore B, Miskovski K, Stupar M, Ng H. Reducing the Prevalence of Alzheimer’s Disease: modifible risk factors or social determinants of health [en línea]. Sydney: Alzheimer’s Australia NSW; 2015. Disponible en: https://nsw.fightdementia.org.au/sites/default/files/NSW/documents/Discussion_Pap
13. Sandra K. Pope. Will a healthy lifestyle help prevent Alzheimer’s disease? Annu Rev Pub Health [en línea]. 2003; 24:111–32. doi: 10.1146/annurev.publhealth.24.100901.141015.
14. Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med. 2011; 269:107-17.
15. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, AntikainenR, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized con-trolled trial. Lancet. 2015; 385:2255-63.
16. Menéndez González M. Estilo de vida y riesgo de padecer demencia. Arch Med [en línea]. 2011 [citado 3 Abr 2017];7(31): [aprox. 16 p.]. Disponible en: http://www.archivosdemedicina.com/medicina-de-familia/estilo-de-vida-y-riesgo-de-padecer-demencia.pdf
17. Flicker L. Modifiable Lifestyle Risk Factors for Alzheimer's Disease. J Alzheimer's Dis. 2010; 20(3):803-811. Disponible en: http://content.iospress.com/articles/journal-of-alzheimers-disease/jad091624?resultNum
18. Martín P. Nutrición y demencia – resumen ejecutivo. Londres: Alzheimer’s Disease International (ADI); 2014.
19. Carnero Pardo C, Escamilla Sevilla F. “Enfermedad de Alzheimer: factores de riesgo y protectores”. En: Martínez Lage JM, Berthier Torres M: “Alzheimer 2002: teoría y práctica”. Madrid: Aula Médica Ediciones; 2002.
20. Dudkowiak R, Gryglas A, Poniewierka E. The role of diet and antioxidants in the prevention of Alzheimer's disease. J Med Sci [en línea]. 2016 [citado 3 Abr 2017]; 85(3):205-212. Disponible en: http://web.b.ebscohost.com/ehost/detail/detail?sid=e89bfc39-9925-40fc-bafb
21. Caballer García J. Los ácidos grasos omega-3 en la prevención
de la enfermedad de Alzheimer. Alzheimer Real Invest Demenc [en línea]. 2011 [citado 4 Abr 2017];49:12-18 Disponible en: http://www.revistaalzheimer.com
22. Rodrigo Valenzuela B. Ácido Docohexanoico (DHA): Una perspectiva nutricional para la prevención de la Enfermedad de Alzheimer. Rev Chil Nutr [en línea]. 2008 [citado 4 Abr 2017]; 35(Supl 1):250-261. Disponible en: http://www.scielo.cl/pdf/rchnut/v35s1/art01.pdf
23. Hussein N. Yassine, MDAMA Neurol. Association of Docosahexaenoic Acid Supplementation with Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers a Review; 2017. Disponible en: http://web.a.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=5cdc4421-2b50-400b-958a-
24. Cruz-Tioba E. Efecto antioxidante de flavonoides contra la toxicidad del amiloide-β fracción 25-35: modelo conductual de Alzheimer. Arch Neuroc. 2005;10(23): Disponible en: http://web.a.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=5cdc4421-2b50-
25. Escamilla Jiménez CI, Cuevas Martínez EY, Fonseca JG. Flavonoides y sus acciones antioxidantes [en línea]. Rev Fac Med UNAM. 2009 [citado 4 Abr 2017]; 52(2):73-75. Disponible en: http://web.a.ebscohost.com/ehost/detail/detail?vid=6&sid=224cd0ca-b701-433d-a436-0255721
Published
2018-12-15
How to Cite
1.
Terrado Quevedo SP, Serrano Durán C, Galano Guzmán ZG, Betancourt Pulsán A, Jiménez de Castro Morgado MI. Alzheimer’s disease, some modifiable risk factors. Rev Inf Cient [Internet]. 2018 Dec. 15 [cited 2025 Apr. 3];97(5):1031-42. Available from: https://revinfcientifica.sld.cu/index.php/ric/article/view/2124
Issue
Section
Review Articles
